On the stock market since 2020, it operates in the world of health and science. It has 46 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
There is $28.4M in the vault; even if every debt were paid off, $16.4M would remain.
A loss of $2.6M against $0 in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, ORYZF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ORYZF is a high-risk stock — not yet profitable, and its future rides on its product catching on.